Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Director departure Notes underwriting agrmnt
|
Adamis Pharmaceuticals Corp (ADMP)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/21/2023 |
8-K
| Quarterly results |
05/15/2023 |
8-K
| Quarterly results |
03/16/2023 |
8-K
| Quarterly results |
11/14/2022 |
8-K
| Quarterly results |
08/10/2022 |
8-K
| Quarterly results |
05/16/2022 |
8-K
| Quarterly results |
03/31/2022 |
8-K
| Quarterly results |
11/22/2021 |
8-K
| Quarterly results |
04/15/2021 |
8-K
| Quarterly results |
11/09/2020 |
8-K
| Quarterly results |
08/17/2020 |
8-K
| Quarterly results |
05/18/2020 |
8-K
| Quarterly results |
03/30/2020 |
8-K
| Quarterly results |
11/12/2019 |
8-K
| Quarterly results |
08/08/2019 |
8-K
| Quarterly results |
05/09/2019 |
8-K
| Quarterly results |
11/14/2018 |
8-K
| Quarterly results |
08/10/2018 |
8-K
| Quarterly results |
11/16/2006 |
8-K
| Quarterly results
Docs:
|
"Cellegy Reports September 30, 2006 Quarter Financial Results Quakertown, Pennsylvania - November 15, 2006 --Cellegy Pharmaceuticals, Inc. announced its third quarter 2006 financial results today. Revenues for the three months ended September 30, 2006 were $172,000 compared to $1,738,000 during the same period in 2005. Prior year revenues for the third quarter included $1,252,000 in Biosyn grant revenue, $257,000 in product sales and $109,000 in licensing revenues. Revenues for the nine months ended September 30, 2006 were $2,635,000 compared to $10,804,000 for the same period in 2005. These included licensing revenues of $452,000 and $6,950,000 for the nine months ended September 30, 2006 and 2005, respectively. Research and development expenses for the three months ended September 30, 200..." |
|
03/31/2006 |
8-K
| Quarterly results |
03/31/2005 |
8-K
| Quarterly results
Docs:
|
"Cellegy Pharmaceuticals Reports 2004 Financial Results",
"BUSINESS UPDATE BY CELLEGY CHAIRMAN Brisbane, California, March 29, 2005 - Cellegy Pharmaceuticals, Inc. . In a conference call today regarding year-end 2004 results and developments at Cellegy Pharmaceuticals, Richard C. Williams, Chairman and interim CEO of the company, provided an update on progress made in several key areas. In a conference call in early January 2005 shortly after he assumed the position of interim CEO, Mr. Williams reported that the company would be striving to accomplish in 2005 several key elements of redirection under his leadership, and that the company would provide an update once accomplishments were realized. Key actions identified in January included:" |
|
11/10/2004 |
8-K
| Quarterly results |
08/10/2004 |
8-K
| Quarterly results |
05/06/2004 |
8-K
| Quarterly results |
03/25/2004 |
8-K
| Quarterly results |
11/06/2003 |
8-K
| Quarterly results |
|
|